Social Cognition Deficits and Psychopathic Traits in Young People Seeking Mental Health Treatment

A van Zwieten; J Meyer; DF Hermens; IB Hickie; DJ Hawes; N Glozier; SL Naismith; EM Scott; RSC Lee; AJ Guastella

Journal article

Social Cognition Deficits and Psychopathic Traits in Young People Seeking Mental Health Treatment

A van Zwieten, J Meyer, DF Hermens, IB Hickie, DJ Hawes, N Glozier, SL Naismith, EM Scott, RSC Lee, AJ Guastella

Plos One | PUBLIC LIBRARY SCIENCE | Published : 2013

DOI: 10.1371/journal.pone.0067753

Download PDF

Abstract

Antisocial behaviours and psychopathic traits place an individual at risk for criminality, mental illness, substance dependence, and psychosocial dysfunction. Social cognition deficits appear to be associated with psychopathic traits and are believed to contribute to interpersonal dysfunction. Most research investigating the relationship of these traits with social cognition has been conducted either in children or adult forensic settings. We investigated whether psychopathic traits were associated with social cognition in 91 young people presenting for mental healthcare (aged between 15 and 25 years). Participants completed symptom severity measures, neuropsychological tests, the Reading th..

View full abstract

University of Melbourne Researchers

Rico Lee Author

Related Projects (2)

EMERGING SEVERE MENTAL ILLNESS IN YOUNG PEOPLE

Mental disorders, such as psychotic and severe mood disorders, are the largest cause of disability in Australia. However, there is still lit..

PREVENTIVE AND EARLY INTERVENTION STRATEGIES IN EMERGING MENTAL DISORDERS IN YOUNG PEOPLE

The Centre will be developed through the extension of a youth psychiatry clinical research program of international standing across Melbourn..

Grants

Awarded by NSW Ministry of Health

Funding Acknowledgements

AJG, DFH, and IBH were supported by an NHMRC Australia Fellowship awarded to IBH (No. 464914). DFH was supported by a grant from the NSW Ministry of Health, Mental Health and Drug & Alcohol Office. SLN was funded by an NHMRC Clinical Research Fellowship (No. 402864). This research was further supported by an NHMRC Program Grant (No. 350241), an ARC linkage Grant (LP110100513) and a Centres of Clinical Research Excellence Grant (No. 264611). EMS and IBH have received educational and research programs/grants that are supported by the pharmaceutical industry (including Servier, Pfizer, AstraZeneca, and Eli Lilly). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.